[Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase â
¢/â
£ extranodal nasal-type natural killer/T cell lymphoma].
Zhonghua Yi Xue Za Zhi
; 101(16): 1178-1181, 2021 Apr 27.
Article
em Zh
| MEDLINE
| ID: mdl-33902250
ABSTRACT
The data of 9 patients with stage â
¢/â
£ extranodal nasal-type natural killer/T cell lymphoma from August 2019 to August 2020 in People's Hospital of Zhengzhou University was retrospectively analyzed. All the patients were treated with the programmed cell death-1 (PD-1) inhibitor combined with P-GemoX-DEX (gemcitabine+oxaliplatin+dexamethasone+peraspartase) regimen as the first-line treatment. After 4 cycles of treatment, positron emission tomography/computed tomography (PET/CT) was used to evaluate the curative effect, and adverse reactions were also observed. The median follow-up time was 7 months. The overall response rate, complete and partial remission rate was 9/9, 6/9 and 3/9, respectively. The main adverse event was hematological toxicity, with 6 cases of grade â
/â
¡ neutropenia, and no immune-related adverse events were reported.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma Extranodal de Células T-NK
Tipo de estudo:
Observational_studies
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2021
Tipo de documento:
Article